Professor Angray Kang, BSc (Hons), PhD
Professor of Immunotechnology
Email: email@example.comTelephone: +44 (0) 207 882 7158Room Number: G82, Blizard Building, Institute of Dentistry
1979-1983 Kings (Chelsea College) University of London B.Sc. Microbiology 1st Class Honours.
1983-1986 University of East Anglia Ph.D. Biochemistry (Institute of Food Research Norwich, supervisor Prof. Henry W-S. Chan). The research was supported by an AFRC studentship and directed towards generating antibodies against mycotoxins (aflatoxin & sterigmatocystin) and developing non-isotopic immunoassays.
1986-1987 Post doctoral research (SERC) at University of Durham UK with Professor Don Boulter.
1987-1989 Post doctoral research (SERC) at University of Sheffield UK with Professor Dennis Burton.
1989-1990 Visiting post doctoral researcher at The Scripps Research Institute with Professor Richard A. Lerner.
1990-1999 Assistant Professor Molecular Biology, The Scripps Research Institute.
Between 1999 and the return to academia in 2005 held various posts of increasing responsibility in drug discovery and development in biopharmaceutical companies (Abgenix Inc, Diversa Corporation and Avanir Pharmaceuticals).
2005-2011 Reader in Molecular Applied Biosciences at the University of Westminster.
2011-2021 Reader in Molecular Cell Biology Queen Mary University of London
2021- present Professor of Immunotechnology Queen Mary University of London
Research: The Ask Lab
Awarded Fellowship of the Higher Education Authority. Supervised PhD, DClinDent, MSc , BSc, iBSc, FY1 and FY2 project students. Developed and rolled out a novel approach to engage students in research via the SSC component in the new BDS curriculum. Participated in delivery of BDS Year 1 (Basic Sciences) and Year 3 (SSC), MSc Oral Biology and MSc Experimental Oral Pathology MSc. Introduced lectures on the potential of therapeutic use of antibodies in dentistry. Course director for Msc Experimental Oral Pathology and module lead on Laboratory Techniques (Theory). Active internal PhD progression panel member for PhD students across SMD and SBCS.
Recombinant antibody technology development and application.
Saxena G, Moore JM, Jones M, Pryce G, Ali L, Leisegang GR, Vijay V, Loveless S, Robertson NP, Schmierer K.(2020). Detecting and predicting neutralization of alemtuzumab responses in MS. Neurology neuroimmunology & neuroinflammation vol. 7, (4)10.1212/NXI.0000000000000767 https://qmro.qmul.ac.uk/xmlui/handle/123456789/65277
Ali L, Saxena G, Jones M, Leisegang GR, Gammon L, Gnanapavan S, Giovannoni G, Schmierer K, Baker D, Kang AS.(2020). A cell-based assay for the detection of neutralizing antibodies against alemtuzumab. BioTechniques: the journal of laboratory technology for bioresearch 10.2144/btn-2019-0122 https://qmro.qmul.ac.uk/xmlui/handle/123456789/62960
Baker D, Ali L, Saxena G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S, Munger KC, Samkoff L.(2020). The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies. Frontiers in Immunology vol. 11, (124) 10.3389/fimmu.2020.00124 https://qmro.qmul.ac.uk/xmlui/handle/123456789/62968
Saxena GK, Theocharopoulos I, Aziz NT, Jones M, Gnanapavan S, Giovannoni G, Schmierer K, Garnett JA et al.(2020). GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains. Scientific Reports vol. 10, (1) Article 1860, 10.1038/s41598-020-58041-3 https://qmro.qmul.ac.uk/xmlui/handle/123456789/62684
Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S, Giovannoni G, Schmierer K.(2018). Alemtuzumab depletion failure can occur in multiple sclerosis. Immunology vol. 154, (2) 253-260. 10.1111/imm.12879 https://qmro.qmul.ac.uk/xmlui/handle/123456789/31849
Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis. Baker, D., Asardag, A. N., Quinn, O. A., Efimov, A., & Kang, A. S. (2021). Hum Antibodies. doi:10.3233/HAB-210453
Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review. Bqain, M., Efimov, A., Baker, D., & Kang, A. S. Hum Antibodies (2021).. doi:10.3233/HAB-210449
Immunogenicity of biologics used in the treatment of moderate to severe psoriasis. Patel, V., Efimov, A., Baker, D., & Kang, A. S. (2021). Human Antibodies, 29(3), 171-178. doi:10.3233/HAB-210447